TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33827828
Drug: Targeted strengthening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted strengthening physiotherapist-led treatment
Study: 33827828
Drug: Standardised stretching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised stretching physiotherapist-led treatment
Study: 32664175
Drug: Methotrexate tablets,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate tablets, leflunomide, and UC‐MSC
Study: 35485559
Drug: Combined ACL
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined ACL reconstruction and ALL augmentation with internal bracing (ALL‐IB)
Study: 35596802
Drug: Hybrid telerehabilitation
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid telerehabilitation program (12-week PFMT program including 2 face-to-face sessions, 2-weekly video sessions, follow-up by physiotherapist, re-evaluation teleconsultation at 6 and 16 weeks, face-to-face consultation at 12 weeks)
Study: 35596802
Drug: Conventional program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional program (2 initial individual sessions followed by twice-weekly group classes, all consultations face-to-face)
Study: 33200257
Drug: Odanacatib (ODN)
Normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odanacatib (ODN) 50 mg once weekly
Study: 35674985
Drug: Ropivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine plus 5 mg nalbuphine
Study: 35674985
Drug: Ropivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine plus 10 mg nalbuphine
Study: 35674985
Drug: Ropivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine plus 20 mg nalbuphine
Study: 35674985
Drug: Ropivacaine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (30 mL 0.1% ropivacaine + 0.9% normal saline)
Study: 32186691
Drug: Online Mindfulness-Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online Mindfulness-Based Cognitive Therapy
Study: 34968470
Drug: Radiation dose
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation dose to the bladder (D2 cm3)
Study: 34968470
Drug: Radiation dose
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation dose to the urethra (D0.1 cm3)
Study: 34968470
Drug: Radiation dose
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation dose to the urethra and bladder
Study: 34825782
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg/day for 5 days
Study: 34825782
Drug: Crizotinib 250
Normalized name: crizotinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crizotinib 250 mg single dose
Study: 34825782
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Esomeprazole and Crizotinib)
Study: 34127619
Drug: Ambulatory inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambulatory inhaled nitric oxide
Study: 32197246
Drug: Microsurgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microsurgical treatment of IPL BAVM
Study: 35930557
Drug: Fact-box styled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fact-box styled message comparing risks of COVID-19 and vaccine
Study: 35930557
Drug: Timeline styled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timeline styled message describing the development process of COVID-19 mRNA vaccines
Study: 33849608
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly selinexor (100 mg), once weekly bortezomib (1.3 mg/m2), and 40 mg per week dexamethasone (XVd)
Study: 33849608
Drug: Standard twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard twice weekly bortezomib and 80 mg per week dexamethasone (Vd)
Study: 33322129
Drug: Placebo (PLAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLAC) - told they would receive 6 mg/kg of caffeine but received a placebo
Study: 32381429
Drug: PPAR‐fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPAR‐fatty acids metabolism pathways
Study: 32381429
Drug: Neural‐hormone regulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neural‐hormone regulation pathways
Study: 33941080
Drug: Galcanezumab 120
Normalized name: Galcanezumab 120 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galcanezumab 120 mg subcutaneous injection monthly with a loading dose of 240 mg
Study: 35448950
Drug: Etomidate 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate 0.2 mg/kg IV followed by etomidate 0.05 mg/kg IV (group E)
Study: 35448950
Drug: Ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.5 mg/kg IV, then etomidate 0.1 mg/kg IV, followed by etomidate 0.05 mg/kg IV (group KE)
Study: 34642756
Drug: 1 cup
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 cup (1CB, 180 g) of canned beans
Study: 34642756
Drug: ½ cup
Approvals — FDA: no, EMA: no, PMDA: no
Description: ½ cup (½CB, 90 g) of canned beans
Study: 34982716
Drug: Mobile Link
Normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile Link intervention (automated twice-weekly SMS and voice messages)
Study: 35712855
Drug: Bedtime restriction
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime restriction therapy
Study: 33939629
Drug: Antischistosomal mass
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antischistosomal mass drug administration (MDA) with praziquantel
Study: 32973176
Drug: all-trans retinoic
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: all-trans retinoic acid (ATRA) 45 mg/m2 orally, days 1–15/cycle in combination with gemcitabine-nab-paclitaxel chemotherapy
Study: 32973176
Drug: gemcitabine-nab-paclitaxel chemotherapy
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: gemcitabine-nab-paclitaxel chemotherapy
Study: 36056421
Drug: Rib fixation
Normalized name: Ade-Rib
DrugBank: Adenosine (DB00640)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rib fixation and standard pain medication
Study: 36056421
Drug: Standard pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pain medication alone
Study: 32170451
Drug: cONS (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: cONS (2.4 kcal/ml, 125 ml)
Study: 32170451
Drug: sONS (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: sONS (1.5 kcal/ml, 200 ml)
Study: 33692429
Drug: High salinity
Approvals — FDA: no, EMA: no, PMDA: no
Description: High salinity treatment (300-500 mM NaCl)
Study: 32237331
Drug: Huangqin Qingre
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huangqin Qingre Chubi Capsules (HQC)
Study: 35148736
Drug: Intravenous TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous TXA 20 mg/kg preoperatively, followed by 10 mg/kg at 3 and 6 hours postoperatively, and gauze soaked with TXA for 10 minutes before incision closure
Study: 35608683
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no repair treatment)
Study: 35988568
Drug: Half-dose betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Half-dose betamethasone (11·4 mg)
Study: 35988568
Drug: Full-dose betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Full-dose betamethasone (11·4 mg)
Study: 34022073
Drug: Topical formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical formulations containing cannabidiol (CBD) and palmitoylethanolamide (PEA)
Study: 34022073
Drug: Cannabinoid products
Normalized name: Cannabinol
DrugBank: Cannabinol (DB14737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabinoid products (CBD, PEA, and hemp seed oil formulations)
Study: 33260376
Drug: CIT/HOMO/VITE (citicoline
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIT/HOMO/VITE (citicoline 500 mg, homotaurine 50 mg, vitamin E 12 mg) in addition to current topical therapy for 4 months.
Study: 33260376
Drug: Current topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current topical therapy alone for 4 months (after CIT/HOMO/VITE treatment).
Study: 33260376
Drug: Current topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current topical therapy for 4 months followed by CIT/HOMO/VITE for 4 months.
Study: 33260376
Drug: CIT/HOMO/VITE in
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIT/HOMO/VITE in addition to current topical therapy for 4 months followed by topical therapy alone for 4 months.
Study: 34737786
Drug: Comprehensive nursing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comprehensive nursing intervention combined with conventional medication
Study: 34737786
Drug: Conventional medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medication alone
Study: 33253237
Drug: Adaptive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive treatment (n = 20)
Study: 35377244
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of undenatured collagen daily for 24 weeks
Study: 32907521
Drug: Telemedicine group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemedicine group (in-hospital medication evaluation, drug reorganization, medical monitoring, and advice via telemedicine)
Study: 32997386
Drug: Antibiotics prescribed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics prescribed following RTI-related GP consultation
Study: 32997386
Drug: Antibiotics prescribed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics prescribed for infants with DS
Study: 32997386
Drug: Antibiotics prescribed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics prescribed for older children with DS
Study: 33300578
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg Silexan
Study: 33300578
Drug: 640 mg
Normalized name: glycerin 1640 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 640 mg Silexan
Study: 33300578
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg lorazepam (active control)
Study: 37349747
Drug: Dentist-administered cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dentist-administered cognitive behavioural therapy (D-CBT)
Study: 34995344
Drug: Oral azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral azacitidine (Oral‐AZA)
Study: 32663278
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose alcohol (1 standard drink for women, 2 drinks for men)
Study: 32663278
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose alcohol (3 standard drinks for women, 4 drinks for men)
Study: 33307857
Drug: Telemedicine group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemedicine group (monitoring and data transmission twice per day, telephone call, and 2 home visits)
Study: 33307857
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (daily visits)
Study: 32398420
Drug: Omalizumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab (300 mg fixed dose or dose-related based on total IgE level and body mass weight)
Study: 35084903
Drug: Pharmacotherapy for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy for CUD
Study: 33285332
Drug: Biperiden (antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biperiden (antagonist of muscarinic receptors)
Study: 33285332
Drug: Amisulpride (antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (antagonist of dopaminergic receptors)
Study: 33285332
Drug: Galantamine (enhancing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (enhancing drug of cholinergic modulation)
Study: 33395210
Drug: Tedizolid phosphate
Normalized name: Tedizolid Phosphate
DrugBank: Tedizolid (DB14569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tedizolid phosphate 200 mg (oral and/or intravenous) once daily for 6 days
Study: 35609525
Drug: Control (routine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (routine maintenance of the chemotherapy unit)
Study: 36204969
Drug: 0.5% silymarin-loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% silymarin-loaded antioxidant serum (SAS) applied twice daily for 4 weeks
Study: 36204969
Drug: 0.5% silymarin-loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% silymarin-loaded antioxidant serum (SAS) with low-dose oral isotretinoin
Study: 33260141
Drug: Caffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated coffee (0.09 g/kg providing 3 mg/kg of caffeine)
Study: 32933954
Drug: Food-related behavioural
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food-related behavioural activation (F-BA) therapy
Study: 33471625
Drug: 20 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g/d of milk protein concentrate
Study: 32435005
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (mydriasis group)
Study: 35088499
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (systemic immunosuppressant, antihistamine, calcium gluconate, topical salicylic acid)
Study: 35088499
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment plus supplemental essential phospholipids (EPL)
Study: 34290085
Drug: Pericapsular nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pericapsular nerve group block (20 mL of adrenalized levobupivacaine 0.50%)
Study: 34290085
Drug: Suprainguinal fascia
Normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - FUSCIA THERAPHY (345)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprainguinal fascia iliaca block (40 mL of adrenalized levobupivacaine 0.25%)
Study: 36118104
Drug: Wearing the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wearing the Serola Sacroiliac Belt during a 10-minute daily repeated strenuous lifting task
Study: 34961705
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg roscovitine
Study: 34961705
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg roscovitine
Study: 34961705
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg roscovitine
Study: 34845507
Drug: Anticoagulant prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant prophylaxis (not specified dosage or duration)
Study: 34633753
Drug: Lubiprostone (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubiprostone (24 mcg twice daily)
Study: 35879756
Drug: Autogenic Inhibition
Normalized name: Autogene cevumeran
DrugBank: Autogene cevumeran (DB17497)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autogenic Inhibition (AI) technique with Conventional therapy
Study: 35879756
Drug: Reciprocal Inhibition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reciprocal Inhibition (RI) technique with Conventional therapy
Study: 34708460
Drug: Curcumin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (500 mg daily)
Study: 33782836
Drug: Ampreloxetine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampreloxetine (10 mg once daily)
Study: 32068002
Drug: Elamipretide 4
Normalized name: Elamipretide
DrugBank: Elamipretide (DB11981)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elamipretide 4 mg once daily for 28 days
Study: 32068002
Drug: Elamipretide 40
Normalized name: Elamipretide
DrugBank: Elamipretide (DB11981)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elamipretide 40 mg once daily for 28 days
Study: 37885327
Drug: Mindfulness-based psychoeducation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based psychoeducation program (twice a week for 4 weeks via video conference)
Study: 32219526
Drug: Intratympanic (IT)
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic (IT) steroids
Study: 32219526
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (IT steroids)
Study: 35927645
Drug: Implant-to-bone surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-to-bone surface ratio
Study: 32713109
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg of azithromycin 3 times weekly for 4 months
Study: 32005336
Drug: Transdiagnostic cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdiagnostic cognitive behavior therapy (CBT)
Study: 32005336
Drug: Disorder-specific cognitive
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disorder-specific cognitive behavior therapy (CBT)
Study: 32005336
Drug: Treatment (CBT)
Normalized name: Hongo Killer Treatment
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (CBT)
Study: 36471362
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of three-dimensional visualization technology with the PBL teaching mode
Study: 32325005
Drug: Home monitoring
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home monitoring program (including home spirometry, reporting of symptoms and side effects, patient-reported outcomes, information, a medication coach, and eConsultations)
Study: 35029629
Drug: Subcutaneous casirivimab
Normalized name: casirivimab
DrugBank: Casirivimab (DB15941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous casirivimab and imdevimab, 1200 mg (600 mg of each)
Study: 35638533
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of rectal diclofenac every 12 hours plus 30 mg of intramuscular pentazocine every 6 hours (group A)
Study: 35638533
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of intramuscular pentazocine every 6 hours (group B)
Study: 32979724
Drug: Mediterranean diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediterranean diet enriched with fatty fish (2 meals/week, ≥150 g cooked filleted fish/meal)
Study: 35264990
Drug: Propranolol (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (120 mg perioperative oral)
Study: 35555638
Drug: Milk permeate
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk permeate solution (GoodSport, GS)
Study: 33231919
Drug: Chronic stress
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic stress (administered via four distinct anthropogenic stressors for 30 minutes daily for 21 days)
Study: 34473018
Drug: Preoperative preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative preparation time ≤2 days
Study: 36155369
Drug: Buprenorphine patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine patch (5 mcg every hour)
Study: 36155369
Drug: Tramadol injections
Normalized name: tramadol Injectable Solution
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol injections (100 mg every 8 hours)
Study: 35975404
Drug: Vibegron 75
Normalized name: vibegron 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibegron 75 mg once daily for 12 weeks
Study: 32321085
Drug: Mindfulness-integrated cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-integrated cognitive behavior therapy (MICBT)
Study: 34011049
Drug: Warming needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warming needle moxibustion treatment for ankylosing spondylitis for 30 days followed by a 6-month follow-up.
Study: 33211166
Drug: Cardiac index
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac index > 2.5 L/min/m2
Study: 35212235
Drug: Intranasal esketamine
Normalized name: esketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intranasal esketamine 84 mg
Study: 34246251
Drug: Non-opioid prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-opioid prescription
Study: 32407242
Drug: Oral ketone
Normalized name: Ketonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketone ester (KE) intake (60 g carbohydrates/h combined with three boluses of 25, 20, and 20 g (R)-3-hydroxybutyl (R)-3-hydroxybutyrate)
Study: 33305513
Drug: sacubitril/valsartan (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: sacubitril/valsartan (target dose 97/103 mg twice daily)
Study: 33305513
Drug: valsartan (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan (target dose 160 mg twice daily)
Study: 32779826
Drug: Over-the-phone supportive
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Over-the-phone supportive care tailored to the needs of oral cancer patients, provided by a health professional
Study: 34186135
Drug: Annual prostate-specific
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual prostate-specific antigen (PSA) tests for 6 years and digital rectal exams (DRE) for 4 years
Study: 35487546
Drug: Discreet pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discreet pill containers
Study: 32330670
Drug: TACTICS implementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: TACTICS implementation (context-tailored implementation approach) after provider training in prolonged exposure therapy (PE) for PTSD.
Study: 32330670
Drug: Provider training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provider training in prolonged exposure therapy (PE) alone.
Study: 32041661
Drug: Prepectoral implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prepectoral implant placement
Study: 32041661
Drug: Subpectoral implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subpectoral implant placement